Global longitudinal strain improves risk assessment after ST-segment elevation myocardial infarction: a comparative prognostic evaluation of left ventricular functional parameters

Magdalena Holzknecht1 · Martin Reindl1 · Christina Tiller1 · Sebastian J. Reinstadler1 · Ivan Lechner1 · Mathias Pamminger2 · Johannes P. Schwaiger3 · Gert Klug1 · Axel Bauer1 · Bernhard Metzler1 · Agnes Mayr2

Received: 30 December 2020 / Accepted: 7 April 2021 / Published online: 21 April 2021
© The Author(s) 2021

Abstract
Aim We aimed to investigate the comparative prognostic value of left ventricular ejection fraction (LVEF), mitral annular plane systolic excursion (MAPSE), fast manual long-axis strain (LAS) and global longitudinal strain (GLS) determined by cardiac magnetic resonance (CMR) in patients after ST-segment elevation myocardial infarction (STEMI).

Methods and results This observational cohort study included 445 acute STEMI patients treated with primary percutaneous coronary intervention (pPCI). Comprehensive CMR examinations were performed 3 [interquartile range (IQR): 2–4] days after pPCI for the determination of left ventricular (LV) functional parameters and infarct characteristics. Primary endpoint was the occurrence of major adverse cardiac events (MACE) defined as composite of death, re-infarction and congestive heart failure. During a follow-up of 16 [IQR: 12–49] months, 48 (11%) patients experienced a MACE. LVEF ($p = 0.023$), MAPSE ($p < 0.001$), LAS ($p < 0.001$) and GLS ($p < 0.001$) were significantly related to MACE. According to receiver operating characteristic analyses, only the area under the curve (AUC) of GLS was significantly higher compared to LVEF ($0.69, 95\% \text{ confidence interval (CI) } 0.64–0.73; p < 0.001 \text{ vs. } 0.60, 95\% \text{ CI } 0.55–0.65; p = 0.031 \text{. AUC difference: } 0.09, p = 0.020$).

After multivariable analysis, GLS emerged as independent predictor of MACE even after adjustment for LV function, infarct size and microvascular obstruction (hazard ratio (HR): 1.13, 95% CI 1.01–1.27; $p = 0.030$), as well as angiographical (HR: 1.13, 95% CI 1.01–1.28; $p = 0.037$) and clinical parameters (HR: 1.16, 95% CI 1.05–1.29; $p = 0.003$).

Conclusion GLS emerged as independent predictor of MACE after adjustment for parameters of LV function and myocardial damage as well as angiographical and clinical characteristics with superior prognostic validity compared to LVEF.

Agnes Mayr
a.mayr@i-med.ac.at

1 University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
2 University Clinic of Radiology, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
3 Department of Internal Medicine, Academic Teaching Hospital Hall in Tirol, Milser Strasse 10, 6060 Hall in Tirol, Austria

* Springer
Introduction

Despite remarkable advances in the management of patients suffering from ST-segment elevation myocardial infarction (STEMI), the risk of subsequent cardiovascular
complications and mortality post-STEMI still remains considerable [1]. Therefore, adequate individual risk assessment following revascularization is of crucial clinical importance [2].

Remnant left ventricular (LV) function is a key determinant in decision-making after acute myocardial infarction and has a strong impact on short- and long-term prognosis [2]. LV function parameters are generally determined by echocardiography, which, however, has numerous limitations, such as moderate spatial resolution, considerable inter-observer variabilities and insufficient acoustic windows [3]. Cardiac magnetic resonance (CMR) imaging represents the current gold standard to determine LV volumes and function and is the optimal imaging modality to evaluate subtle changes in the post-infarcted myocardium [4]. LV ejection fraction (LVEF) is a well-established marker of global LV function and recommended for risk prediction after STEMI with important implications for patient management [2, 5]. Nevertheless, LVEF does not allow the assessment of subtle regional differences in cardiac function, hampering the prognostic accuracy of isolated LVEF assessment [6].

Alternative approaches for the determination of LV function with a more subtle depiction of longitudinal shortening in the course of ischemia are mitral annular plane systolic excursion (MAPSE) and fast manual long-axis strain (LAS) [7–9]. MAPSE, displaying atrioventricular plane motion, and LAS, comparing end-diastolic and end-systolic diameters of the LV, are suggested as easy-to-measure surrogate parameters for LV function due to their fast assessment without the need of an additional software [9, 10]. Finally, global longitudinal strain (GLS) permits to detect delicate changes in post-infarcted myocardium enabling a more accurate assessment of systolic function with superior prognostic validity as compared to LVEF [11–13].

In the context of acute STEMI, GLS has been shown to independently predict major adverse cardiac events (MACE) after revascularized STEMI compared with conventional LVEF [14, 15]. Besides, MAPSE is suggested to provide significant higher prognostic validity than LVEF in this patient population [9]. Also LAS has been shown to predict MACE after acute myocardial infarction over established clinical parameters [8]. However, no study compared the prognostic significance of all of these parameters in terms of predicting hard clinical events so far.

We, therefore, aimed to investigate the comparative prognostic value of LVEF, MAPSE, LAS and GLS by CMR in the acute stage post-STEMI for the occurrence of MACE.

**Methods**

Prior to study inclusion, written informed consent was given by all participants. The study was designed and conducted in compliance with the Declaration of Helsinki and received approval by the research ethics committee of the Medical University of Innsbruck.

**Patient population and endpoint definitions**

For this prospective observational CMR study, patients consecutively enrolled in the “Magnetic Resonance Imaging In Acute ST-Elevation Myocardial Infarction (MARINA-STEMI) trial” (NCT04113356) between 2011 and 2019 were evaluated for inclusion in the final analysis. Inclusion criteria were: first STEMI according to the ESC/ACC/AHA committee criteria [16], revascularization by primary percutaneous coronary intervention (pPCI) within 24 h after onset.
of ischemic symptoms and Killip class < 3 at time of CMR. The following exclusion criteria were applied: inability or unwilling to sign written informed consent, age < 18 years, any history of previous myocardial infarction or coronary intervention, an estimated glomerular filtration rate < 30 mL/min per 1.73 m² and any other contraindication to CMR examination (pacemaker, severe claustrophobia, orbital foreign body, cerebral aneurysm clip, or known or suggested contrast agent allergy to gadolinium) [17].

Primary endpoint of the study was the occurrence of MACE, including all-cause death, myocardial re-infarction and new congestive heart failure after discharge for the index event. Re-infarction was defined according to the redefined ESC/ACC/AHA committee criteria: symptoms of ischemia and/or new significant ST-segment changes with a rise and/or fall of hs-cTnT with at least one value above the 99th percentile upper reference limit in patients with normalized values or increase of 50% in the setting of non-normalized troponin value [16]. New congestive heart failure was determined as first episode of cardiac decompensation requiring intravenous diuretic therapy with or without hospital re-admission [18]. Clinical endpoints were collected via telephone interviews at 6 months, 12 months and then every 12 months thereafter, using a standardized questionnaire. Follow-up investigations were carried out by personnel blinded to all baseline data which checked the declared endpoints afterwards by reviewing the medical records.

Cardiac magnetic resonance imaging

All patients were investigated in supine position on a 1.5 T clinical MR scanner (MAGNETOM Avanto®, Siemens Healthineers AG, Erlangen, Germany) within the first week after treatment with pPCI using an 18-channel body phased-array surface coil together with the integrated 32-channel spine matrix coil. The standardized imaging protocol of our research group was published in detail in previous work [17].

High-resolution cine images in long and short axes covering the LV (10–12 slices) were acquired using a balanced steady-state free precession (bSSFP) sequence with retrospective electrocardiographic (ECG) gating (slice thickness (SL): 8 mm, interslice gap: 2 mm, echo time (TE) 1.19 ms, repetition time (TR) 2.83 ms, matrix 320 × 260, voxel size (VS) 2.6 × 1.8 × 8.0 mm³) parallel imaging mode: GRAPPA (generalized auto-calibrating partial parallel acquisition) with acceleration factor: 2).

For the assessment of LV volumes and LVEF on short-axis cine images, a standard post-processing software (ARGUS; Siemens Healthineers AG, Erlangen, Germany) was applied (Fig. 1, Panel A) with semi-automatic detection of LV endo- and epicardial borders.

Feature tracking analyses were performed by one experienced observer using the commercially available LV specific cvi42 Tissue Tracking software (Circle Cardiovascular Imaging Inc®, Calgary, Canada, v5.1.4), as described previously [14]. LV endocardial and epicardial borders were manually traced at end-diastole in short- and long-axis cine images using a point-and-click approach. Short-axis measurements were conducted at predefined apical, mid-ventricular and basal levels and long-axis data were derived by tracing three standardized planes (2-chamber, 3-chamber as well as 4-chamber views). Papillary muscles were assigned to the LV volume. Based on the 16-segment model, the software algorithm calculated 3-dimensional peak strains and subsequently, by averaging the according peak values of the segments, the global strain parameters: GLS (Fig. 1, Panel b), global radial strain (GRS) and global circumferential strain (GCS).

The standardized measurement procedure for MAPSE has been reported previously [9]. Briefly, MAPSE was measured as the perpendicular distance of the end-systolic mitral annular plane to the end-diastolic plane, measured in regard to the septal attachment of the mitral valve in end-diastole on a long-axis 4-chamber cine view (Fig. 1, Panel c). Intra- and inter-observer variabilities for feature tracking CMR and MAPSE measurements have been published previously [9, 14]. LAS was assessed on a cine 4-chamber view. As described previously [10], the distance between the epicardial border of the LV apex and the middle of a line connecting the origins of the mitral leaflets was measured in end-diastole and end-systole (Fig. 1, Panel D). Thereafter, LAS was calculated with the following formula:

\[ \text{LAS} = \frac{\text{Length}_{\text{end-diastole}} - \text{Length}_{\text{end-systole}}}{\text{Length}_{\text{end-diastole}}} \times 100 \]

An ECG-triggered, phase-sensitive inversion recovery sequence was used to obtain late gadolinium enhancement (LGE) images 15–20 min after application of 0.2 mmol/kg of Gd-DO3A-butriol (Gadovist®, Bayer Vital GmbH, Leverkusen, Germany) with short-axis slices covering the entire left ventricle and TI individually adjusted to null signal from normal myocardium (IR bSSFP sequence with phase-sensitive and magnitude reconstructed images; SL: 8 mm, interslice gap: 2 mm, FoV: 400 × 363 mm, matrix: 256 × 232, VS: 2.2 × 1.6 × 8.0 mm³, TR: 2.9 ms, TE:1.2 ms, FA: 45°, parallel imaging mode: GRAPPA, acceleration factor: 2). For quantification of infarct size (IS), a picture archiving and communication system (PACS) workstation (IMPAX®,
Agfa HealthCare, Bonn, Germany) was used, whereas “hyper-enhancement” was defined as +5 standard deviations above the signal intensity of remote LV myocardium [18, 19]. IS was expressed as percentage of total LV myocardial mass (LVMM). Microvascular obstruction (MVO) was defined as persisting area of “hypo-enhancement” within the hyper-enhanced territory and was also reported as percentage of LVMM [18]. Regions of MVO were included in aggregate IS.

Experienced observers, blinded to clinical and angiographic data, analyzed all CMR images.

Incomplete CMR was defined as premature termination of the investigation due to patient, medical or technical problems.

Statistical analyses

Continuous variables were expressed as median with interquartile range (IQR) and categorical variables as numbers with corresponding percentages. Differences in continuous and categorical variables between two groups were tested by Mann-Whitney U test and Chi-square test, respectively. Univariable and multivariable Cox regression analyses were performed to reveal predictors of MACE. All variables with a $p \leq 0.10$ in univariable analysis were included in multivariable testing. To ensure statistical robustness with respect to our sample size and number of events, 3 multivariable Cox regression models (CMR, angiographical and clinical model) were compiled. The CMR model comprises parameters of LV function and myocardial damage, the angiographical model contains independent predictors of the CMR model adjusted for interventional parameters, whereas in the clinical model, the independent LV function parameter of the angiographical model was adjusted for markers of clinical prognosis. Collinearity was evaluated by the variance inflation factor (VIF), whereas a VIF > 5 was interpreted as relevant collinearity, > 10 as serious collinearity [20]. Receiver operating characteristic (ROC) analyses were applied to evaluate area under the curve (AUC) for the prediction of MACE. ROC curves were compared according to DeLong et al. [21]. Following Rice and Harris, AUC values were categorized as negligible ($\leq 0.55$), small (0.56–0.63), moderate (0.64–0.70) and strong ($\geq 0.71$) [22]. The incremental prognostic value was determined using reclassification analyses via R package ‘PredictABEL’. Continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated. Youden Index was calculated to evaluate the optimal cut-off values for dichotomization of continuous MACE predictors [23]. MACE-free survival was estimated and depicted by the Kaplan–Meier method and differences were assessed by the log-rank test. All tests were 2-tailed and the significance level was set at 0.05. SPSS Statistics v26.0 (IBM, Armonk, New York), MedCalc v19.0.7 (Ostend, Belgium) and R 3.6.1 (The R Foundation, Austria) were used for statistical analyses. The graphic abstract was created with BioRender.com.

Results

Study population

In total, 445 STEMI patients were included in the final analysis. A detailed study flow chart that includes the reasons for exclusion is depicted in Fig. 2.

Median age of the overall cohort was 57 [IQR: 50–66] years and 67 patients (15%) were female. Total ischemia time was in median 197 [IQR: 126-344] minutes. Baseline patient characteristics are provided in detail in Table 1.

CMR parameters

CMR scans were performed at a median of 3 [IQR: 2–4] days after pPCI. Time to CMR did not differ between patients with and without MACE ($p = 0.333$). Table 2 provides an overview of the assessed CMR parameters, separately for patients with and without MACE.

LVEF of the overall population was 53 [IQR: 45–59]%.

MAPSE 9.0 [IQR: 7.4–10.9] mm, LAS $-14.4$ [IQR: $-19.6$ to $-10.0$]% and GLS $-12.0$ [IQR: $-14.0$ to $-10.0$]%.

Infarct characteristics were as follows: IS 14.0 [IQR: 

Fig. 2 Flow diagram of the study cohort. STEMI ST-segment elevation myocardial infarction, FU follow-up, MACE major adverse cardiac events, CMR cardiac magnetic resonance
7.3–23.7% and MVO 0.1 [0.0–1.9]% of LVMM. MVO occurred in 51% (n = 228) of the overall cohort.

Clinical outcome

During a median follow-up time of 16 [IQR: 12–49] months, 48 patients (11%) suffered from MACE (12 deaths, 17 re-infarctions and 19 heart failure events). Patients with MACE were significantly older (p = 0.023) and presented more often with cardiovascular risk factors (diabetes p = 0.012 and hypertension p < 0.001). The number of diseased vessels was higher (p = 0.002) and thrombolysis in myocardial infarction flow post-pPCI was lower in the group with MACE (p = 0.002). Furthermore, peak hs-cTnT values were higher in patients with MACE (p < 0.001).

Table 1  Patient characteristics

|                          | Total population (n = 445) | No MACE (n = 397, 89%) | MACE (n = 48, 11%) | p-value |
|--------------------------|---------------------------|------------------------|--------------------|---------|
| Age, years               | 57 [50–66]                | 57 [49–65]             | 62 [51–72]         | **0.023**|
| Female, n (%)            | 67 (15)                   | 58 (15)                | 9 (19)             | 0.449   |
| Body mass index, kg/m²   | 26.2 [24.6–28.4]          | 26.2 [24.7–28.6]       | 25.9 [24.1–27.8]   | 0.233   |
| Current smoker, n (%)    | 246 (55)                  | 220 (55)               | 26 (54)            | 0.869   |
| Hyperlipidemia, n (%)    | 265 (60)                  | 238 (60)               | 27 (56)            | 0.622   |
| Diabetes mellitus, n (%) | 40 (9)                    | 31 (8)                 | 9 (19)             | **0.012**|
| Family history, n (%)    | 140 (32)                  | 127 (32)               | 13 (27)            | 0.489   |
| Hypertension, n (%)      | 230 (52)                  | 192 (48)               | 38 (79)            | <0.001  |
| Systolic blood pressure, mmHg | 132 [115–152]   | 132 [115–152]         | 138 [116–156]     | 0.677   |
| Diastolic blood pressure, mmHg | 80 [71–95]            | 80 [71–94]            | 85 [70–99]        | 0.712   |
| Heart rate, bpm          | 72 [63–85]                | 71 [62–85]             | 74 [63–85]        | 0.831   |
| Total ischemia time, min | 197 [126–344]             | 195 [124–332]         | 223 [137–593]     | 0.146   |
| Door-to-balloon time, min | 37 [18–70]             | 37 [18–69]            | 44 [19–99]        | 0.263   |
| Culprit lesion, n (%)    |                          |                       |                    | 0.083   |
| RCA                      | 182 (41)                  | 165 (41)               | 17 (35)            |         |
| LAD                      | 202 (45)                  | 173 (44)               | 29 (61)            |         |
| LCX                      | 58 (13)                   | 56 (14)                | 2 (4)              |         |
| RI                       | 3 (1)                     | 3 (1)                  | 0 (0)              |         |
| Infarct location, n (%)  |                          |                       |                    | **0.019**|
| Non-anterior             | 238 (54)                  | 220 (55)               | 18 (37)            |         |
| Anterior                 | 207 (46)                  | 177 (45)               | 30 (63)            |         |
| Number of affected vessels, n (%) |            |                       |                    | **0.002**|
| 1                        | 271 (61)                  | 248 (62)               | 23 (48)            |         |
| 2                        | 127 (28)                  | 114 (29)               | 13 (27)            |         |
| 3                        | 47 (11)                   | 35 (9)                 | 12 (25)            |         |
| TIMI flow pre-pPCI, n (%)|                          |                       |                    | 0.277   |
| 0                        | 288 (65)                  | 252 (63)               | 36 (75)            |         |
| 1                        | 64 (14)                   | 58 (15)                | 6 (12.5)           |         |
| 2                        | 74 (17)                   | 68 (17)                | 6 (12.5)           |         |
| 3                        | 19 (4)                    | 19 (5)                 | 0 (0)              |         |
| TIMI flow post-pPCI, n (%)|                          |                       |                    | **0.002**|
| 0                        | 8 (2)                     | 7 (2)                  | 1 (2)              |         |
| 1                        | 6 (1)                     | 3 (1)                  | 3 (6)              |         |
| 2                        | 46 (10)                   | 37 (9)                 | 9 (19)             |         |
| 3                        | 385 (87)                  | 350 (88)               | 35 (73)            |         |
| Peak hs-cTnT, ng/l       | 4925 [2456–8564]          | 4666 [2188–8015]       | 7438 [4278–14751]  | <0.001  |

Bold values denote statistical significance

MACE major adverse cardiac events, RCA right coronary artery, LAD left anterior descending artery, LCX left circumflex artery, RI Ramus intermedius, TIMI thrombolysis in myocardial infarction, pPCI primary percutaneous coronary intervention, Hs-cTnT high-sensitivity cardiac troponin T
Table 2  CMR results

|                      | Total population\((n=445)\) | No MACE \((n=397, 89\%)\) | MACE \((n=48, 11\%)\) | \(p\)-value |
|----------------------|-------------------------------|-------------------------|-----------------------|-------------|
| LVEDV, ml            | 152 [127–174]                 | 151 [127–174]           | 160 [131–174]         | 0.350       |
| LVESV, ml            | 72 [55–91]                    | 72 [55–88]              | 80 [60–107]           | **0.041**   |
| LVEF, %              | 53 [45–59]                    | 53 [45–59]              | 50 [40–55]            | **0.023**   |
| GLS, %               | −12.0 [−14.0 to −10.0]        | −12.3 [−14.1 to −10.2]  | −10.6 [−12.4 to −7.7] | < **0.001** |
| GRS, %               | 27.3 [21.5–32.3]              | 27.9 [21.7–32.6]        | 24.6 [18.8–29.8]      | **0.030**   |
| GCS, %               | −13.8 [−15.5 to −11.6]        | −14.0 [−15.6 to −11.7]  | −12.2 [−13.7 to −9.3] | < **0.001** |
| MAPSE, mm            | 9.0 [7.4–10.9]                | 9.1 [7.5–11.0]          | 8.0 [6.1–9.3]         | < **0.001** |
| LAS, %               | −14.4 [−19.6 to −10.0]        | −15.2 [−20.0 to −10.6]  | −11.2 [−14.9 to −7.2] | < **0.001** |
| IS, % of LVMM        | 14.0 [7.3–23.7]               | 13.9 [7.0–23.5]         | 17.8 [8.8–25.7]       | 0.095       |
| MVO, \(n\) (%)      | 228 (51)                      | 196 (49)                | 32 (67)               | **0.024**   |
| MVO, % of LVMM       | 0.1 [0.0–1.9]                 | 0.0 [0.0–1.8]           | 0.9 [0.0–4.4]         | **0.031**   |

Bold values denote statistical significance

LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, LVEF left ventricular ejection fraction, GLS global longitudinal strain, GRS global radial strain, GCS global circumferential strain, MAPSE mitral annular plane systolic excursion, LAS fast manual long-axis strain, IS infarct size, LVMM left ventricular myocardial mass, MVO microvascular obstruction

Fig. 3  LV functional parameters and clinical outcome. Kaplan–Meier curves displaying event-free survival according to best cut-offs of GLS, LAS, MAPSE and LVEF. MACE major adverse cardiac events, LVEF left ventricular ejection fraction, MAPSE mitral annular plane systolic excursion, LAS fast manual long-axis strain, STEMI ST-segment elevation myocardial infarction
CMR measures and major adverse cardiovascular events

LVEF was significantly lower in patients with MACE (p = 0.023). All three LV myocardial strain parameters (GLS, GRS and GCS) were significantly related to MACE (all p < 0.05). Accordingly, GLS was higher in the MACE group (-10.6% vs. -12.3%, p < 0.001). MAPSE was significantly lower in patients with MACE (8.0 mm vs. 9.1 mm, p < 0.001), whereas LAS was higher in the MACE group (-11.2% vs. -15.2%, p < 0.001). Among parameters of myocardial damage, the presence (p = 0.024) and the extent of MVO (p = 0.031) were associated with MACE (Table 2).

As illustrated by the Kaplan–Meier curves (Fig. 3), GLS > -11.2%, MAPSE < 8.6 mm, LAS > -13.5% and LVEF < 51% were associated with a significantly lower MACE-free survival (all p < 0.001).

GLS showed the highest AUC for the prediction of MACE (0.69, 95% CI: 0.64–0.73, p < 0.001). In comparison to all investigated LV functional parameters, only the AUC of GLS was significantly higher than the AUC of LVEF (0.60, 95% CI: 0.55–0.65, p = 0.031, AUC difference: 0.09, p = 0.020, Table 3, Model 1) (Fig. 4).

In reclassification analysis, the addition of GLS to LVEF (continuous net reclassification improvement (NRI): 0.60 [95% CI: 0.31–0.88], p < 0.001; IDI: 0.02 [95% CI: 0.01–0.04], p < 0.001), LAS to LVEF (continuous NRI: 0.51 [95% CI: 0.23–0.79], p < 0.001; IDI: 0.02 [95% CI: 0.01–0.03], p = 0.005) and MAPSE to LVEF (continuous NRI: 0.52 [95% CI: 0.24–0.81], p < 0.001; IDI: 0.02 [95% CI: 0.01–0.03], p = 0.005) led to a significant improvement in risk classification.

In a multivariable CMR model (Table 4) including LVEF, MAPSE, GLS, LAS, extent of MVO and IS, only GLS (HR: 1.13, 95% CI: 1.01–1.27, p = 0.030) and LAS (HR: 1.07, 95% CI: 1.01–1.14, p = 0.019) significantly predicted MACE. As demonstrated by the clinical model (Table 4), the association between GLS and MACE remained significant (p = 0.003) after adjustment for clinical determinants of MACE (age, hypertension, diabetes, number of diseased vessels, peak hs-cTnT). All variables included in multivariable analysis showed a VIF of < 3 (CMR model: 1.3–2.2, angiographical model: 1.1–1.9, clinical model: 1.1–1.6).

**Table 3** C-statistics for the prediction of MACE

| Variables | AUC  | 95% CI | p-value | AUC increment | ROC comparison |
|-----------|------|--------|---------|---------------|----------------|
| Model 1   |      |        |         |               |                |
| LVEF, %   | 0.60 | 0.55–0.65 | 0.031   | –             | –              |
| LV GLS, % | 0.69 | 0.64–0.73 | <0.001  | 0.09          | 0.020          |
| Model 2   |      |        |         |               |                |
| LVEF, %   | 0.60 | 0.55–0.65 | 0.031   | –             | –              |
| LAS, %    | 0.67 | 0.62–0.70 | <0.001  | 0.07          | 0.164          |
| Model 3   |      |        |         |               |                |
| LVEF, %   | 0.60 | 0.55–0.65 | 0.031   | –             | –              |
| MAPSE, mm | 0.66 | 0.61–0.70 | <0.001  | 0.06          | 0.246          |

Bold values denote statistical significance

_AUC_ area under the curve, _ROC_ receiver operating curve, _MACE_ major adverse cardiac events, _LVEF_ left ventricular ejection fraction, _GLS_ global longitudinal strain, _MAPSE_ mitral annular plane systolic excursion, _LAS_ fast manual long-axis strain.
Discussion

To the best of our knowledge, this is the first comprehensive study investigating the comparative prognostic value of all currently available functional CMR parameters including LVEF, MAPSE, GLS and LAS in acute STEMI patients revascularized by pPCI. The major findings can be summarized as follows: LVEF, MAPSE, GLS and LAS were significantly associated with MACE. The prognostic value of MAPSE, GLS and LAS was incremental to LVEF. GLS emerged as independent predictor of MACE after adjustment for measures of LV function (LVEF, MAPSE, LAS), myocardial injury (IS and MVO) angiographical (number of diseased vessels, infarct location) and clinical parameters (age, hypertension, diabetes, peak hs-cTnT) with superior prognostic validity compared to LVEF. Taken together, feature tracking of GLS using CMR independently enables risk assessment after STEMI and expands the prognostic significance of LVEF.

Prognostic value and timing of imaging

As recommended by the current guidelines, myocardial function should be determined in all patients with acute STEMI before hospital discharge [2]. Due to its broad and easy availability, LVEF by echocardiography is usually the preferred LV functional parameter for risk stratification after STEMI in daily clinical routine [2]. Over the last years, analyses of myocardial strain and MAPSE have primarily been driven by echocardiography; however, echocardiographic techniques are limited by moderate spatial resolution and often hampered by an insufficient acoustic window [24, 25]. Indeed, the assessment of myocardial function by CMR has increasingly focused on risk stratification after STEMI [26, 27]. Due to its high spatial and temporal resolution, CMR enables accurate assessment of GLS by tracking the endo- and epicardial borders precisely. These semi-automatic post-processing mechanisms allow quick and easy analysis of LV deformation parameters [15]. On the other hand,
echocardiography is a broadly available, cost-effective imaging tool, but more susceptible to poor image quality [24]. This could be due to the examiner as well as the person to be examined complicating the exact assessment of these parameters [24]. Even though CMR accurately depicts myocardial alterations, local experience might influence the use of CMR vs. echocardiography-guided risk assessment strategies.

In a previous work, we revealed CMR assessed MAPSE to independently predict the occurrence of hard clinical events with superior prognostic validity than LVEF following acute STEMI [9]. However, the current work expands our previous findings by highlighting MAPSE to be significantly associated with MACE incremental to LVEF in an even larger cohort of STEMI patients. As a great advantage, MAPSE can be quickly evaluated on cine CMR images without the need of a special post-processing software.

LAS is another parameter of global systolic function which can be easily assessed from standard cine CMR images [8] without proprietary software. Schuster and colleagues demonstrated in a large cohort of patients with acute myocardial infarction a strong association of impaired LAS with MACE occurrence. In their study, GLS was also found to be a significant predictor of MACE if calculated separately from LAS. However, it was not included in multivariable analysis due to its high correlation with LAS as stated by the authors. On the basis of the VIF, we could include all LV functional parameters in multivariable analysis and could demonstrate GLS and LAS to independently predict MACE in the CMR model. However, GLS, but not LAS, remained an independent predictor of MACE following acute STEMI after adjustment for clinical parameters. Since LAS assesses the relative distances between mitral annular and apical planes in long-axis views, it is unable to provide regional myocardial information which might be of major prognostic relevance in the context of acute myocardial infarction [8].

Feature tracking CMR is a high-resolution investigation of global and regional myocardial deformation by tracking the actual myocardial borders and following them subsequently [15, 28]. Depicting the 3-dimensional LV deformation during the cardiac cycle is challenging due to the complex interplay between longitudinal and circumferential shortening, radial thickening and torsion [29]. Especially longitudinal myocardial fibers seem to be sensitive to ischemia, possibly due to their subendocardial location [11]. However, there is an ongoing debate whether myocardial fiber architecture has an impact on cardiac function after myocardial infarction. Our research group recently demonstrated feature tracking CMR gained GLS to strongly and independently predict the occurrence of MACE in the medium term after acute STEMI [14]. This fits well with other CMR studies [15, 30] supporting the findings of our present study. Finally, we could confirm and expand previous results [14, 15, 30] by showing that GLS remained a significant predictor of MACE even after adjustment for IS and MVO, which are considered as major determinants of worse prognosis following STEMI [31], angiographical and clinical parameters. Interestingly, Backhaus and colleagues revealed that infarct-related artery alterations after myocardial infarction might have an impact on subsequent prognosis [32]. In their analysis, patients with left circumflex as infarct-related artery, GLS best predicted MACE, whereas in left anterior descending artery and right coronary artery infarcts, left atrial total strain was more expressive for prognosis assessment. This underlines the complexity of pathophysiological mechanisms leading to myocardial deformation.

As emphasized previously, the optimal timing for measurement of myocardial deformation is unclear [33]. In accordance with other CMR studies investigating the prognostic value of LV functional parameters [8, 9, 14, 15, 30], we performed CMR imaging within a week after STEMI. However, in contrast to Schuster et al. [8], time to CMR in our cohort did not differ between patients with and without MACE. This might be explained by the fact, that we only included hemodynamic stable STEMI patients (Killip < 3) which were able to undergo CMR investigations within the proposed time range. Future studies in this direction are needed to validate the optimal time point for myocardial deformation measurement with CMR after STEMI.

**Clinical implications and future directions**

We could demonstrate that GLS as a single marker independently improved personalized risk stratification after STEMI with superior prognostic validity compared to LVEF. On the other hand, we demonstrated that the predictive value of LAS or MAPSE in addition to LVEF was higher than that of LVEF alone. These combinations might serve as good alternatives for LV-based risk assessment after STEMI, if GLS is not available. As advantages, LAS and MAPSE are faster to measure and require no proprietary software compared to GLS [33]. However, additional time and software required for GLS assessment are considered worthwhile since prognostic information beyond established LV functional parameters is improved [34]. GLS is considered as more sensitive marker for LV function-based prognosis assessment [15] and might be impaired despite preserved LVEF as we demonstrated in our cohort. In the current era of pPCI, a relevant portion of STEMI patients presents with a near normal or even preserved LVEF and would therefore be considered as low-risk patients [35]. Nevertheless, the absolute number of MACE is substantial in this subgroup with preserved LVEF [36]. This corroborates the limited prognostic validity of LVEF and advances the need for novel risk stratification tools in STEMI patients with preserved LVEF. Recently, GLS has increasingly come into focus not only
for risk stratification but also for representing a potential new therapeutic target [34]. In fact, the METOCARD-CNIC trial by Podlesnikar et al. revealed that early intravenous administration of metoprolol in anterior STEMI patients was accompanied by improved LV strain at 1 week and with fewer patients having altered strain at 1 week and at 6 months than the control group [37]. However, the benefit of anti-remodeling treatment strategies, especially in patients with preserved LVEF (but maybe altered strain values) has not been clarified so far. Finally, the manner in which imaging-driven strategies of myocardial deformation assessment will support daily clinical decision-making requires further research [33, 38].

Limitations

In this observational CMR study, only stable patients (Killip class < 3) with acute and first-time STEMI were included; hence, our findings may not be transferable to hemodynamically less stable patients or to patients with previous myocardial infarction. Notably, the vast majority of STEMI patients presents with Killip class < 3 [39]. Although, quantitative native T1 mapping and post-contrast T1 mapping (including extracellular volume), as well as T2* mapping, were recently suggested for improved risk stratification following STEMI [40–43], we could not include these measurements due to unavailability of these sequences for a considerable number of patients. Furthermore, CMR investigations were conducted at a single time point and within a week after the index event for LV deformation measurements. Defining the optimal time frame for performing CMR remains another important area for future research. Even though CMR is the optimal imaging tool for quantification of LV parameters [4], it exhibits limitations, such as restricted availability, higher costs and center-specific expertise. Furthermore, LGE CMR has some contraindications, such as non-magnetic resonance conditional pacemakers or other ferromagnetic structures and implants, renal function impairment and claustrophobia. In contrast, echocardiography is widely available, has significantly lower costs, is faster in image acquisition and can be used “bed-side”. However, echocardiography is highly examiner-dependent and limited acoustic windows may complicate accurate quantification of LV deformation [3, 25]. Further studies are needed to investigate the comparative predictive value of all LV deformation parameters as assessed by echocardiography and CMR. The lack of a validation cohort and the relatively small number of events in our cohort represent an important limitation of the study. Finally, inconsistencies between commercially available software for strain assessment with acceptable differences for GLS and GCS, but not for GRS have to be taken into account [44].

Conclusion

GLS by feature tracking CMR emerged as independent predictor of MACE with superior prognostic validity compared to LVEF. The combination of LAS or MAPSE with LVEF revealed a significantly better prognostic value than LVEF alone and could be used as alternatives for risk stratification after STEMI.

Funding Open access funding provided by University of Innsbruck and Medical University of Innsbruck. This study was supported by grants from the ‘Austrian Society of Cardiology’, ‘Tiroler Wissenschafts-förderung’ and ‘Austrian Science Fund’ (FWF): KLI 772-B.

Declarations

Conflict of interest All authors have declared no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Pedersen F, Butrymovich V, Kelbaek H, Wachtell K, Helqvist S, Kastrup J et al (2014) Short- and long-term cause of death in patients treated with primary pci for stemi. J Am Coll Cardiol 64(20):2101–2108
2. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al (2018) 2017 Esc guidelines for the management of acute myocardial infarction in patients presenting with st-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with st-segment elevation of the European Society of Cardiology (Esc). Eur Heart J 39(2):119–177
3. Kirkpatrick JN, Vannan MA, Narula J, Lang RM (2007) Echocardiography in heart failure: applications, utility, and new horizons. J Am Coll Cardiol. 50(5):381–396
4. Klug G, Metzler B (2013) Assessing myocardial recovery following st-segment elevation myocardial infarction: short- and long-term perspectives using cardiovascular magnetic resonance. Expert Rev Cardiovasc Ther 11(2):203–219
5. Mollema SA, Nucifora G, Bax JJ (2009) Prognostic value of echocardiography after acute myocardial infarction. Heart 95(21):1732–1745
6. Dagens N, Hindricks G (2013) Risk stratification after myocardial infarction: is left ventricular ejection fraction enough to prevent sudden cardiac death? Eur Heart J 34(26):1964–1971

7. Hu K, Liu D, Herrmann S, Niemann M, Gaudron PD, Voelker W et al (2013) Clinical implications of mitral annular plane systolic excursion for patients with cardiovascular disease. Eur J Cardiovasc Imaging 14(3):205–212

8. Schuster A, Backhaus SJ, Stermaier T, Kowallick JT, Stulle A, Koschakla A et al (2019) Fast manual long-axis strain assessment provides optimized cardiovascular event prediction following myocardial infarction. Eur J Heart Cardiovasc Imaging 20(11):1262–1270

9. Mayr A, Pamminger M, Reindl M, Greulich S, Reinstadler SJ, Tiller C et al (2020) Mitral annular plane systolic excursion by cardiac MR is an easy tool for optimized prognosis assessment in st-elevation myocardial infarction. Eur Radiol 30(1):620–629

10. Riffel JH, Andre F, Maertens M, Rost F, Keller MG, Giusca S et al (2016) Risk stratification after myocardial infarction: is left ventricular ejection fraction enough to prevent sudden cardiac death? Eur Heart J 37(15):1196–1207

11. Hu K, Liu D, Herrmann S, Niemann M, Gaudron PD, Voelker W et al (2013) Clinical implications of mitral annular plane systolic excursion for patients with cardiovascular disease. Eur J Cardiovasc Imaging 14(3):205–212

12. Ersboll M, Valeur N, Mogensen UM, Andersen MJ, Møller JM, Velazquez EJ et al (2013) Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction. J Am Coll Cardiol 61(23):2365–2373

13. Kammerlander AA, Dona C, Nitsche C, Koschutnik M, Schonbauer R, Duca F et al (2020) Feature tracking of global longitudinal strain by using cardiovascular MRI improves risk stratification in heart failure with preserved ejection fraction. Radiology 296(2):290–298

14. Reindl M, Tiller C, Holzknecht M, Lechner I, Beck A, Plappert D et al (2019) Prognostic implications of global longitudinal strain by feature-tracking cardiac magnetic resonance in st-elevation myocardial infarction. Cardiovascular Imaging 12(11):E009404

15. Eitel I, Stermaier T, Lange T, Rommel KP, Koschakla A, Kowallick JT et al (2018) Cardiac magnetic resonance myocardial feature tracking for optimized prediction of cardiovascular events following myocardial infarction. JACC Cardiovasc Imaging 11(10):1433–1444

16. Thysen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow J et al (2018) Fourth universal definition of myocardial infarction. Eur Heart J 40(3):237–269

17. Reinstadler SJ, Klug G, Feistritzer HJ, Mayr A, Harrasser B, Mair J et al (2013) Association of Copeptin with myocardial infarct size and myocardial function after st-segment elevation myocardial infarction. Heart 99(20):1525–1529

18. Reindl M, Reinstadler SJ, Feistritzer HJ, Theurl M, Basic D, Eigler C et al (2017) Relation of low-density lipoprotein cholesterol with microvascular injury and clinical outcome in revascularized st-elevation myocardial infarction. J Am Heart Assoc. https://doi.org/10.1161/JAHA.117.006957

19. Bondarenko O, Beek AM, Hofman MB, Kuhl HP, Twisk JW, Van Dockum WG et al (2005) Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson 7(2):481–485

20. Orrien RMA (2007) Caution regarding rules of thumb for variance inflation factors. Qual Quant. 41(5):673–690

21. Delong ER, Delong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845

22. Rice ME, Harris GT (2005) Comparing effect sizes in follow-up studies: ROC area, Cohen’s D and R. Law Hum Behav 29(5):615–620

23. Youden WJ (1950) Index for rating diagnostic tests. Cancer 3(1):32–35

24. Hu K, Liu D, Niemann M, Herrmann S, Gaudron PD, Ertl G et al (2013) Methods for assessment of left ventricular systolic function in technically difficult patients with poor imaging quality. J Am Soc Echocardiogr 26(2):105–113

25. Gjesdal O, Almeida AL, Hopp E, Beintes JO, Lunde K, Smith HJ et al (2014) Long axis strain by MRI and echocardiography in a postmyocardial infarct population. J Magn Reson Imaging 40(5):1247–1251

26. Lonborg J, Engstrom T (2017) Cardiovascular magnetic resonance for risk stratification in patients with st-segment-elevation myocardial infarction: a novel tool to tailor therapy or emperor’s new clothes? Circ Cardiovasc Imaging. https://doi.org/10.1161/CIRCVINMAGING.117.007108

27. Reinstadler SJ, Thiele H, Eitel I (2015) Risk stratification by cardiac magnetic resonance imaging after st-elevation myocardial infarction. Curr Opin Cardiol 30(6):681–689

28. Schuster A, Hor KN, Kowallick JT, Beerbaum P, Kuttu S (2016) Cardiovascular magnetic resonance myocardial feature tracking: concepts and clinical applications. Circ Cardiovasc Imaging 9(4):E004077

29. Moore CC, Lugo-Olivieri CH, Mcveigh ER, Zerhouni EA (2000) Three-dimensional systolic strain patterns in the normal human left ventricle: characterization with tagged MR imaging. Radiology 214(2):453–466

30. Gavara J, Rodriguez-Palamares JF, Valente F, Momneneu JV, Lopez-Lereu MP, Bonanad C et al (2018) Prognostic value of strain by tissue tracking cardiac magnetic resonance after st-segment elevation myocardial infarction. Jacc Cardiovasc Imaging 11(10):1448–1457

31. Eitel I, De Waha S, Wohrle J, Fuernau G, Lurz P, Pauschinger M et al (2014) Comprehensive prognosis assessment by CMR imaging after st-segment elevation myocardial infarction. J Am Coll Cardiol 64(12):1217–1226

32. Backhaus SJ, Kowallick JT, Stermaier T, Lange T, Koschakla A, Navarra JL et al (2020) Culprit vessel-related myocardial mechanics and prognostic implications following acute myocardial infarction. Clin Res Cardiol 109(3):339–349

33. Farzaneh-Far A, Romano S (2019) Measuring longitudinal left ventricular function and strain using cardiovascular magnetic resonance imaging. Eur Heart J Cardiovasc Imaging 21(11):1259–1261

34. Bodi V (2019) Strain by feature tracking: a short summary of the journey of CMR in stemi. JACC Cardiovasc Imaging 12(7 Pt 1):1199–1201

35. Hanania G, Cambou JP, Gueret P, Vaur L, Blanchard D, Lablanche JM et al (2004) Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry. Heart (British Cardiac Society). 90(12):1404–1410

36. Ng VG, Lansky AJ, Meller S, Witzenbichler B, Guagliumi G, Serruys PW et al (2014) The prognostic importance of left ventricular systolic function in patients with acute myocardial infarction: the HORIZONS-AMI trial. Eur Heart J 35(21):1568–1575

37. Podlesnikar T, Pizarro G, Fernandez-Jimenez R, Montero-Cabezas JM, Sanchez-Gonzalez J, Bucciarelli-Ducci C et al (2019) Effect of early metoprolol during st-segment elevation myocardial infarction on left ventricular strain: feature-tracking cardiovascular magnetic resonance substudy from the metocard-CNIC trial. JACC Cardiovasc Imaging 12(7 Pt 1):1188–1198
38. Kammerlander AA (2020) Feature tracking by cardiovascular magnetic resonance imaging: the new gold standard for systolic function? JACC Cardiovasc Imaging 13(4):948–950

39. Scholz KH, Maier SKG, Maier LS, Lengenfelder B, Jacobshagen C, Jung J et al (2018) Impact of treatment delay on mortality in st-segment elevation myocardial infarction (Stemi) patients presenting with and without haemodynamic instability: results from the german prospective. Multicentre Fitt-Stemi Trial. Eur Heart J 39(13):1065–1074

40. Carrick D, Haig C, Ahmed N, Mcentegart M, Petrie MC, Eteiba H et al (2016) Myocardial hemorrhage after acute reperfused st-segment-elevation myocardial infarction: relation to microvascular obstruction and prognostic significance. Circ Cardiovasc Imaging 9(1):E004148

41. Carrick D, Haig C, Rauhalammi S, Ahmed N, Mordi I, Mcentegart M et al (2016) Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused st-elevation myocardial infarction survivors. Eur Heart J 37(13):1044–1059

42. Reindl M, Eitel I, Reinstadler SJ (2020) Role of cardiac magnetic resonance to improve risk prediction following acute st-elevation myocardial infarction. J Clin Med. 9(4):1041

43. Reinstadler SJ, Stiermaier T, Reindl M, Feistritzer HJ, Fuernau G, Eitel C et al (2019) Intramyocardial haemorrhage and prognosis after st-elevation myocardial infarction. Eur Heart J Cardiovasc Imaging 20(2):138–146

44. Schuster A, Stahnke VC, Unterberg-Buchwald C, Kowallick JT, Lamata P, Steinmetz M et al (2015) Cardiovascular magnetic resonance feature-tracking assessment of myocardial mechanics: intervendor agreement and considerations regarding reproducibility. Clin Radiol 70(9):989–998